Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PALM3 | A6NDB9 | Paralemmin-3 | Predicted intracellular proteins | Immune mediation | 10 | 0.50 | ||||
| PITX3 | O75364 | Pituitary homeobox 3 (Homeobox protein PITX3) (Paired-like homeodomain transcription factor 3) | Plasma proteinsPredicted secreted proteins | Immune mediation | 10 | 0.50 | ||||
| CAP2 | P40123 | Adenylyl cyclase-associated protein 2 (CAP 2) | Cancer-related genesPredicted intracellular proteins | Fusion and delivery mediation | 9 | 0.50 | ||||
| DNJC9 | Q8WXX5 | DnaJ homolog subfamily C member 9 (HDJC9) (DnaJ protein SB73) | Essential proteinsPredicted intracellular proteins | Other mediation | 9 | 0.50 | ||||
| HLAE | P13747 | HLA class I histocompatibility antigen, alpha chain E (MHC class I antigen E) [Cleaved into: Soluble HLA class I histocompatibility antigen, alpha chain E (sHLA-E)] | Plasma proteinsPredicted membrane proteinsPredicted secreted proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 9 | 0.50 | |||
| PLCG1 | P19174 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (EC 3.1.4.11) (PLC-148) (Phosphoinositide phospholipase C-gamma-1) (Phospholipase C-II) (PLC-II) (Phospholipase C-gamma-1) (PLC-gamma-1) | Cancer-related genesEnzymesMetabolic proteins | Clinical-translation mediationFusion and delivery mediationImmune mediation | 9 | 0.50 | ||||
| S39AA | Q9ULF5 | Zinc transporter ZIP10 (Solute carrier family 39 member 10) (Zrt- and Irt-like protein 10) (ZIP-10) | Essential proteinsMetabolic proteinsPredicted intracellular proteins | 7 | Fusion and delivery mediationImmune mediation | 9 | 0.50 | |||
| UB2D2 | P62837 | Ubiquitin-conjugating enzyme E2 D2 (EC 2.3.2.23) ((E3-independent) E2 ubiquitin-conjugating enzyme D2) (EC 2.3.2.24) (E2 ubiquitin-conjugating enzyme D2) (Ubiquitin carrier protein D2) (Ubiquitin-conjugating enzyme E2(17)KB 2) (Ubiquitin-conjugating enzyme E2-17 kDa 2) (Ubiquitin-protein ligase D2) (p53-regulated ubiquitin-conjugating enzyme 1) | EnzymesMetabolic proteinsPlasma proteins | Clinical-translation mediationImmune mediationMetabolism mediation | 9 | 0.50 | ||||
| ARAF | P10398 | Serine/threonine-protein kinase A-Raf (EC 2.7.11.1) (Proto-oncogene A-Raf) (Proto-oncogene A-Raf-1) (Proto-oncogene Pks) | EnzymesHuman disease related genesPlasma proteins | Clinical-translation mediationReceptor-signaling mediation | 8 | 0.50 | ||||
| CMYA5 | Q8N3K9 | Cardiomyopathy-associated protein 5 (Dystrobrevin-binding protein 2) (Genethonin-3) (Myospryn) (SPRY domain-containing protein 2) (Tripartite motif-containing protein 76) | Predicted intracellular proteins | Other mediation | 8 | 0.50 | ||||
| ERBB2 | P04626 | Receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19 protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-type cell surface receptor HER2) (p185erbB2) (CD antigen CD340) | Cancer-related genesCD markersDisease related genes | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 8 | 0.50 | |||
| G3P | P04406 | Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-) | EnzymesEssential proteinsFDA approved drug targets | Muscular atrophyMuscular dystrophy | Clinical-translation mediationImmune mediationMetabolism mediation | 8 | 0.50 | |||
| OTU1 | Q5VVQ6 | Ubiquitin thioesterase OTU1 (EC 3.4.19.12) (DUBA-8) (HIV-1-induced protease 7) (HIN-7) (HsHIN7) (OTU domain-containing protein 2) | EnzymesPredicted intracellular proteins | Fusion and delivery mediationMetabolism mediation | 8 | 0.50 | ||||
| PLVAP | Q9BX97 | Plasmalemma vesicle-associated protein (Fenestrated endothelial-linked structure protein) (Plasmalemma vesicle protein 1) (PV-1) | Disease related genesHuman disease related genesPlasma proteins | 1 | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 8 | 0.50 | |||
| PTCA | Q14761 | Protein tyrosine phosphatase receptor type C-associated protein (PTPRC-associated protein) (CD45-associated protein) (CD45-AP) (Lymphocyte phosphatase-associated phosphoprotein) | Predicted intracellular proteins | 1 | Other mediation | 8 | 0.50 | |||
| SASH3 | O75995 | SAM and SH3 domain-containing protein 3 (SH3 protein expressed in lymphocytes homolog) | Disease related genesPredicted intracellular proteins | Adhesion and uptake mediationImmune mediation | 8 | 0.50 | ||||
| TN13B | Q9Y275 | Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form] | Cancer-related genesCD markersFDA approved drug targets | 1 | Lupus erythematosusLymphomaMultiple myeloma | Adhesion and uptake mediationClinical-translation mediationImmune mediation | 8 | 0.50 | ||
| ANK3 | Q12955 | Ankyrin-3 (ANK-3) (Ankyrin-G) | Cancer-related genesDisease related genesHuman disease related genes | Adhesion and uptake mediationFusion and delivery mediationMetabolism mediation | 7 | 0.50 | ||||
| APOD | P05090 | Apolipoprotein D (Apo-D) (ApoD) | Cancer-related genesCandidate cardiovascular disease genesPlasma proteins | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 7 | 0.50 | ||||
| CALD1 | Q05682 | Caldesmon (CDM) | Plasma proteinsPredicted intracellular proteins | Fusion and delivery mediation | 7 | 0.50 | ||||
| CC038 | Q5JPI3 | Uncharacterized protein C3orf38 | Predicted intracellular proteins | Other mediation | 7 | 0.50 | ||||
| EI2BB | P49770 | Translation initiation factor eIF2B subunit beta (S20I15) (S20III15) (eIF2B GDP-GTP exchange factor subunit beta) | Disease related genesEssential proteinsHuman disease related genes | Immune mediationMetabolism mediation | 7 | 0.50 | ||||
| FAD1 | Q8NFF5 | Bifunctional FAD diphosphatase/FAD synthase [Includes: FAD diphosphatase (EC 3.6.1.18) (EC 3.6.1.22) (FAD pyrophosphatase) (FADPPase) (FADHy) (NADH diphosphatase); FAD synthase (FADSy) (EC 2.7.7.2) (FMN adenylyltransferase) (FMNAT) (Flavin adenine dinucleotide synthase)] | Disease related genesEnzymesHuman disease related genes | Metabolism mediation | 7 | 0.50 | ||||
| ITSN2 | Q9NZM3 | Intersectin-2 (SH3 domain-containing protein 1B) (SH3P18) (SH3P18-like WASP-associated protein) | Predicted intracellular proteins | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 7 | 0.50 | ||||
| PCDA1 | Q9Y5I3 | Protocadherin alpha-1 (PCDH-alpha-1) | Predicted membrane proteinsPredicted secreted proteins | 1 | Adhesion and uptake mediation | 7 | 0.50 |